Allergy-Immunology
Cardiology
Endocrinology
Gastroenterology
General Internal Medicine
Geriatric Medicine
Hematology / Oncology
Hepatology
Hospital Medicine
Immunotherapy
Infectious Diseases
Nephrology / Hypertension
Pulmonary & Critical Care
Rheumatology
Sports Medicine

Bibliography 2000

2004 | 2003 | 2002 | 2001 | 2000 | 1999

  1. Argiris A, Murren JR. Clinical use of the camptothecins at year 2000. Principles and Practices of  Oncology, Vol. 14, Num. 2; Updates 2000.

  2. Argiris A, Seropian S, Cooper DL. High dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for patients with primary refractory or relapsed Hodgkin's disease, Annals of Oncology, 11:665-72, 2000.

  3. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Michalets EL, Feldman MD, Davidson CJ, Tsai H. Thrombotic thrombocytopenic purpura associated with clopidogrel. NEJM, 342:1773-1777 2000.

  4. Bennett CL, Schwartz D, Sipler A, Lane DR, Chmiel JS, Yarnold PR, Campo R, Goetz M, DeHovitz JA, Weinstein RA. Delays in tuberculosis isolation and suspicion among persons hospitalized with HIV related pneumonia. Chest, 117:110-116, 2000.

  5. Bennett CL, Stinson TJ, Laver JH, Bishop MR, Godwin JE, Tallman MS. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymph, 37(1-2): 65-70, 2000.

  6. Bennett CL, Stinson TJ, Vogel V, Robertson L, Leedy D, O'Brien P, Hobbs J, Sutton T, Ruckdeschel JC, Chirikos TN, Weiner RS, Ramsey MM and Wicha MS. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institues/Northwestern University clinical trials costs and charges project. J Clin Oncol, 18:2805-2810, 2000.

  7. Arozullah AM, Yarnold PR, Weinstein RA, Nwadiaro Nduka, McIlraith TB, Chmiel JS, Sipler AM, Chan Cheeling, Goetz MB, Schwartz DN, Bennett CL. A new preadmission staging system for predicting inpatient mortality from HIV-associated pneumocystis carinii pneumonia in the early-HAART era. Amer J Respiratory and Critical Care Medicine, 161:1081-1086, 2000.

  8. Curtis JR, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related pneumocystis carinii pneumonia. Am J Respir Crit Care Med, 162: 393-398, 2000.

  9. Djulbegovic B, Lacevic M, Cantor A, Fields K, Bennett CL, Adams JR, Kuderer NM and Lyman GH. The uncertainty prinicple and industry-sponosred research, Lancet, 356:635-638, 2000.

  10. Fitzner K., Coughlin S Tomori C, Bennett CL. Health care in Hong Kong and mainland China: one country, two systems? Health Policy, 53:147-155, 2000.

  11. Kim SP, Moran EM, Bowes ED, Tennant AG, Bennett CL. The anti-androgen transfer. The Prostate Journal, 2:88-93, 2000.

  12. Knox KS, Adams JR, Djulbegovic B, Stinson TS, Tomori C, Bennett CL. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Annals of Oncology, 11:1-5, 2000.

  13. Knox KS, Hounshell JB, Tomori C, Bennett CL. The role of culturally specific interventions in the improvement of cancer prevention and screening rates among minority populations. Oncology News International, 2000, (in press).

  14. Lindau ST, Tomori C, McCarville MA, Bennett CL. Improving rates of cervical cancer screening and pap smear follow-up for low income women with limited health literacy. Cancer Invest, 2000, (in press).

  15. Manangan LP, Bennett CL, Tablan N, Simonds DN, Pugliese G, Collazo E, Jarvis WR. Nosocomial tuberculosis prevention measures among two groups of U.S. hospital, 1992 to 1996, Chest, 117: 380-384, 2000.

  16. Nadler RB, Koch LE, Calhoun E, Campbell P, Pruden DL, Bennett CL, Yarnold PR, Schaeffer A. IL-1B and TNF-a in prostatic secretions are key indicators in the evaluation of men with chronic prostatitis. J Urology, 164:214-218, 2000.

  17. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, Bennett CL. Combined androgen blockade with non-steroidal anti-androgens for advanced prostate cancer: a systematic review. Urology, 57(4): 727-732, 2000.

  18. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Annals of Internal Medicine, 132:566-577, 2000.

  19. Sipler AM, Tomori C, Bennett CL. Does Bias Exist in Economic Analyses of New Agents? Managed Care & Cancer, 2(1): 26-31, 2000.

  20. Sipler AM, Tomori C, Bennett CL. Pharmaceutical sponsored economic analyses: Can they be believed? Oncology Economics, 1(1):32-33, 2000.

  21. Sipler AM, Tomori C, Bennett CL. Improving Cancer Research for Ethnic Minorities and the Medically Underserved. Oncology News International, 2000, (in press).

  22. Slimack N, Tomori C, Bennett CL. Quality of life assessment in culturally diverse populations: A summary of findings from the 1999 Robert H. Lurie Comprehensive Cancer Center Health Policy Symposium. Oncology News International, 2000, (in press).

  23. Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennett CL. Economic analysis of a phase III study of G-CSF versus placebo following allogenic blood stem cell transplantation. Bone Marrow Transpl, 26(6):663-666, 2000.

  24. Thrasher JB, Deeths J, Bennett CL, Iyer P, dineen MK, Zhai S, Figg WD, McLeod DG. Comparative study of the clinical effects of two dosing regiments of flutamide. Molecular Urology 4(3):259-263, 2000.

  25. Tomori C, Sipler AM, Bennett CL. Women with HIV are at greater risk for cervical cancer. Primary Care & Cancer, 20(4):11-13, 2000.

  26. Tomori C, Sipler AM, Bennett CL. HIV-Infected Women at Increased Risk for Developing Invasive Cervical Cancer. Oncology News International, 8(12):2,22, 2000.

  27. Benson III AB, et al. Colon and rectal cancer: treatment guidelines for patients: version I. InTouch, September pp63-99, 2000.

  28. Benson III AB, Olopade OI, Ratain MJ, Radmaker A, Mobarhan S, Stucky-Marshall L, French S, Dolan ME. Chronic daily low dose of 4-methyl-5 (2-pyrazinyl)-1,2 dithiole-3-thione (oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clin Cancer Res, 6:3870-3877, 2000.

  29. Asbury RF, Lipsitz S, Graham D, FalksonCI, Baez L, Benson AB. Treatment of squamous cell esophageal cancer with topotecan: and Easter Cooperative Oncology Group Study (E2293). Am J Clin Oncol (CCT) 23:45-46, 2000.

  30. Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, Benson III AB. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296. Oncology, 58: 215-218, 2000.

  31. Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson III AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Study (E5283), J Clin Oncol, 18:148-157, 2000.

  32. Kornblau S, Benson III AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S. Management of cancer treatment-related diarrhea: Issues and therapeutic strategies. J Pain Sympt Manage 19: 118-129, 2000.

  33. Boggio L, Pooley R, Roth SI, Winter JN. Typhlitis complicating autologous blood stem cell transplantation for breast cancer. Bone Marrow Transpl, 25:321-326, 2000.

  34. Wang P, Gartenhaus R, Sood S, Devoti J, Singer C, Dorante G, Hilton E. Detection of borrelia DNA in circulating monocytes as evidence of persistent Lyme Disease. J Spirochetal and Tick-Borne Diseases, 7:16-19, 2000.

  35. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer, 88: 2047-2053, 2000

  36. Gradishar WJ, Soff G, Liv J, Cisneros A, French S, et al. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Oncology, 58: 324-333, 2000.

  37. Hull R, Pineo G, Francis C, Green D, et al. A double-blind, randomized comparison of low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery versus warfarin in hip-arthroplasty patients. Arch Int Med, 160:2199-2207,2000.

  38. Hull R, Pineo G, Francis C, Green D, et al. A double-blind, randomized comparison of low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital versus warfarin-placebo in hip-arthroplasty patients. Arch Int Med, 160:2208-2215,2000.

  39. Kaufman D, Ragahavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol, 18:1921-1927, 2000

  40. Kwaan HC, Wang J, Svoboda K, Declerk PJ. Plasminogen activator inhibitor 1 may promote tumor growth through inhibition of apoptosis. BJ Cancer, 82(10):1702-1708, 2000.

  41. Guo Y, A-R Higazi A, Arakelian A, Sachias B, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA. A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor death in vivo. FASEB, 14:1400-1410, 2000.

  42. Hong JJ, Kwaan HC. Current management of thrombotic thrombocytopenic purpura. Hematology, 4, 461-469, 2000.

  43. Powles R, Mehta J, Kulkami S, Treleaven J, Millar B, Marsden J, Shepherd V, Rowland A, Sirohi B, Tait D, Horton C, Long S, Singhal S. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet;355:1231-1237, 2000.

  44. Brauner DJ, Muir JC, Sachs GA. Dementia and osteoporosis: lessons from treating non-dementia illnesses in patients with dementia. JAMA, 283:3230-3235, 2000.

  45. Lee ES, MacGregor-Schafer J, Yao K, England G, O'Regan RM, De Los Reyes A, Jordan VC. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6:4893-4899, 2000.

  46. MacGreor-Schafer JI, Lee ES, O'Regan RM, Jordan VC. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 6:4373-4380, 2000.

  47. Yao K, Lee ES, Bentrem D, England G, MacGregor-Schafer JI, O’Regan RM, Jordan VC. Antitumor action of physiologic estradiol on tamoxifen-stimulated tumors in athymic mice. Clin Cancer Res, 6:2028-2036, 2000.

  48. Paice JA, Ferrans CE, Lashley F, Shott S, Vizgirda V, Pitrak D. Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 19:45-52, 2000.

  49. Paice JA, Shott S, Oldenburg FP, Zeller J, Swanson B. Efficacy of a vibratory stimulus for the relief of HIV-associated neuropathic pain. Pain, 84:291-296, 2000.

  50. Paice JA. Outcome measures in interventional pain management. Pain Digest, 2000 (in press).

  51. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain, 85: 291-296, 2000.

  52. Pasche B. TßR-I(6A): a new cancer susceptibility gene. Cancer Research Alert, 1:114-117, 2000.

  53. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies F, Shima Y, Tai Y, Rosen ST, Avraham S, Kharbanda S, Anderson K. SHP2 Mediates the Protective Effect of Interleukin-6 Against Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells. Journal of Biological Chemistry. 275:27845-27850, 2000.

  54. Shanmugam M, Krett NL, Maizels ET, Murad FM, Cutler RE, Smith LM, Rosen ST, Hunzicker-Dunn M. Regulation of the protein kinase C delta isoform by estrogen in the MCF-7 human breast cancer cell line, Endocrinology, 2000 (in press).

  55. Singhal S, Powles R, Kulkarni S, Treleaven J, Sirohi B, Millar B, Shepherd V, Saso R, Rowland A, Long S, Cabral S, Horton C, Mehta J. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Bone Marrow Transpl, 25:501-505, 2000.

  56. Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Mehta J, Spoon D, Anaissie E, Barlogie B, Munshi N. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transpl, 25:483-487, 2000.

  57. Kulkarni S, Powles R, Treleaven J, Singhal S, Horton C, Sirohi B, Bhagawati N, Tait D, Saso R, Killick S, Pinkerton R, Atra A, Meller S, Mehta J. Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single center over a period of 26 years. Bone Marrow Transpl, 25:365-370, 2000.

  58. Powles R, Sirohi B, Kulkarni S, Bhagwati N, Saso R, Raje N, Horton C, Singhal S, Mehta J, Treleaven J. Acute lymphoblastic leukemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma – a phase I/II feasibility and tolerance study in 17 patients. Bone Marrow Transpl, 25:949-956, 2000.

  59. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, Bhagwati N, Horton C, Singhal S, Mehta J. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transpl, 25:533-539, 2000.

  60. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, François C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood; 95:90-95, 2000.

  61. Tallman MS, Neuberg D, Bennett JM, Francois C, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM. Acute megakaryocytic leukemia: The Eastern Cooperative Oncology Group Experience. Blood, 96:2405-2411, 2000.

  62. Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Wiesdorf D, Keating A, Gale RP, Geller RB, Laughlin MJ, Lazarus HM, Luger S, McCarthy PL, Rowe JM, Saez RA, Vowels MR, Horowitz MM. Effect of postremission chemotherapy prior to HLA-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood, 96(4):1254-1258, 2000.

  63. Lee S, Tallman MS, Oken MM, Cassileth PA, Bennett JM, Wiernik PH, Rowe, JM. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Leukemia , 14:1345-1348,2000.

  64. Lum BL, Advani R, Villena J, Dugan K, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Greenberg PL, Sikic BI. The pharmacokinetics of etoposide and mitoxantrone in a trial of mdr modulation with valspodar (PSC 833) in acute myeloid leukemia. J Clin Oncol, 2000 (in press).

  65. Slack JL, Willman CL, Andersen JW, Li Y-P, Viswanatha D, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical follow-up of adult APL patients with the type V PML-RARa isoform: Results from Intergroup protocol 0129. Blood, 95 (2):398-403, 2000.

  66. Duvic M, Friedman-Kien AE, Looney DJ, Miles SA, Myskowski PL, Scadden DT, Von Roenn J, Galpin JE, Groopman J, Yocum RC. Topical treatment of cutaneous lesions of AIDS-related Kaposi’s sarcoma using 9-cis-retinoic acid (alitretinoin): results of phase I-II trials. Arch of Derm, 2000 (in press)

  67. Levine AM, Ping L, Cheung T, Tulpule A, Von Roenn J, Nathwani B, Ratner L. ABVD chemotherapy with G-CSF in HIV infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS Clinical Trials Group study (ACTG#149). J of AIDS , 24:444-450, 2000.

  68. Sparano JA, Lee S, Chen M, Hamilton S, Einzig A, Ambinder R, Henry D, Von Roenn JH. Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide (CDE) plus didanosine and G-CSF in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol, 2000 (in press).

  69. Anderson LM, Krotz S, Weitzman SA, Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Therapy, 7:845-852, 2000.

  70. Kamp DW, Srinivasan M, Weitzman SA. Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J. Invest Med, 49:68-76, 2000.

  71. Miller KA, Chung J, Lo D, Jones JCR, Thimmapaya B, Weitzman SA. Inhibition of laminin-5 production in breast epithelial cells by over expression of p300. J. Biol. Chem, 275:8176-8182, 2000.

  72. DiPersio JE, Shuster M, Winter JN, Abboud C. Mobilization of peripheral blood stem cells by concurrent administration of daniplestim and granulocyte colony-stimulating factor in patients with breast cancer or lymphoma. J Clin Oncol, 18(14):2762-71, 2000.

  73. Hochster HS, Oken MM, Winter JN, Gordon LI, Raphael BG, Bennett JM, Cassileth PA. A phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma:(ECOG 1491): results and long term follow-up – A report from the Eastern Cooperative Oncology Group. J Clin Oncol, 18(5):987-994, 2000.

  74. Lefebvre P, Winter JN, Meng Y, Cohen I. Ex vivo expansion of early and late megakaryocyte progenitors. J Hematother Stem Cell Res, 9(6): 913-21, 2000.

  75. Patel SD, Guo R, Miller WM, Papoutsakis ET, Minster NI, Baum CM, Winter JN. Clinical-scale production of granulocyte progenitor and post-progenitor cells using Daniplestim, Leridistim, progenipoietin, Promegapoietin and autologous plasma. Cytotherapy, 2:85-94, 2000.

  76. Patel SD, Miller WM, Winter JN, Papoutsakis ET. Cell-density dependent proliferation in frequently fed peripheral blood mononuclear cell cultures. Cytotherapy, 2:267-280, 2000.

  77. Patel SD, Papoutsakis ET, Winter JN, Miller WM. The lactate issue revisited: novel feeding protocols to examine inhibitor of cell proliferation and glucose metabolism in hematopoietic cell cultures. Biotechnology Progress, 16(5): 885-92, 2000.